Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07532408) titled 'Romiplostim N01 in the Treatment of Refractory Chemoradiotherapy-induced AA' on April 8.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Aplastic Anemia
Intervention:
Drug: Romiplostim N01
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: April 2026
Target Sample Size: 43
To know more, visit https://clinicaltrials.gov/study/NCT07532408
Disclaimer: Curated by HT Syndication....